OmniAb, Inc. (NASDAQ:OABI) Q4 2025 Earnings Call Transcript March 5, 2026 Operator: Good afternoon, and welcome to OmniAb, Inc.’s First — Fourth Quarter 2025 Financial Results and Business Update ...

Kinaxis Inc. ( KXS:CA) Q4 2025 Earnings Call March 5, 2026 8:30 AM EST Good morning, and welcome to the Kinaxis Inc. Fiscal 2025 Fourth Quarter and Year-end Results Conference Call. [Operator ...

SCOTTSDALE, AZ, UNITED STATES, March 4, 2026 / EINPresswire.com / — Lazarus Alliance Celebrates 26 Years of Pioneering Proactive Cybersecurity ®, Empowering Global Organizations to Eliminate Up to 96% ...

OmniAb, Inc. ( OABI) Q4 2025 Earnings Call March 4, 2026 4:30 PM EST Good afternoon, and welcome to OmniAb, Inc.'s First -- Fourth Quarter 2025 Financial Results and Business Update Conference Call.

BBAI's Q4 revenues slide to $27.3M from $43.8M as Army program volume falls, but record cash, new AI acquisitions and a 2026 growth outlook point to a rebound.

Full Year 2025 Highlights Revenue increased 17% to a record €1,290 millionGenerated profit for the period of €100 million, 7.8% as a percentage of revenueAdjusted EBITDA1 increased 33% to a record ...

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Fluent, Inc. (NASDAQ: FLNT) today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2025, after the ...

EVERTEC, Inc. (NYSE: EVTC) ("Evertec" or the "Company") today announced results for the fourth quarter and full year ended December 31, 2025.

Ginkgo Bioworks Holdings, Inc. today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on ...

Q4 2025 Earnings Call Transcript February 24, 2026Kiniksa Pharmaceuticals, Ltd. misses on earnings expectations.

Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people w ...

Kiniksa Pharmaceuticals(NASDAQ:KNSA) highlighted rapid ARCALYST revenue expansion and expanding treatment adoption across its addressable pericarditis market. The transition from net loss to net ...